<Report lg="SL" xmlns="http://redmap.europa.eu/xml/iPlRp-v2-0#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://redmap.europa.eu/xml/iPlRp-v2-0# iPlRp_v2-0.xsd"><Cover><Ref><Num-Report>A7-0164/2012</Num-Report></Ref><Date>12.7.2012</Date><Blk-Title-Cover><Sigle-Proc>***I</Sigle-Proc><Title-Type>POROČILO</Title-Type><Title><p margin-bottom="0pt" margin-left="70.9pt" margin-right="0pt" margin-top="0pt">o predlogu uredbe Evropskega parlamenta in Sveta o spremembi Uredbe (ES) št. 726/2004 glede farmakovigilance </p></Title><Doc-Ref><p margin-bottom="24pt" margin-left="70.9pt" margin-right="0pt" margin-top="0pt">(COM(2012)0051 – C7‑0034/2012 – 2012/0023(COD))</p></Doc-Ref></Blk-Title-Cover><Body type="COMMITEE" id="815"><p margin-bottom="24pt" margin-left="70.9pt" margin-right="0pt" margin-top="0pt">Odbor za okolje, javno zdravje in varnost hrane</p></Body><Grp-Rap><p margin-bottom="24pt" margin-left="70.9pt" margin-right="0pt" margin-top="0pt">Poročevalka: <Rapporteur id="2327">Linda McAvan</Rapporteur></p></Grp-Rap><Num-PE>PE 486.166v03-00</Num-PE></Cover><Legend><table border-collapse="collapse" margin-left="83.35pt" width="290.55pt" cellspacing="0"><tr><td border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0 5.35pt 0 5.35pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-style="italic" font-weight="bold">Oznake postopkov</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" padding="0 5.35pt 0 5.35pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="36.85pt" margin-right="0pt" margin-top="0pt" text-indent="-36.85pt">       *     Postopek posvetovanja</p><p margin-bottom="0pt" margin-left="36.85pt" margin-right="0pt" margin-top="0pt" text-indent="-36.85pt">   ***     Postopek odobritve</p><p margin-bottom="0pt" margin-left="36.85pt" margin-right="0pt" margin-top="0pt" text-indent="-36.85pt">  ***I     Redni zakonodajni postopek (prva obravnava)</p><p margin-bottom="0pt" margin-left="36.85pt" margin-right="0pt" margin-top="0pt" text-indent="-36.85pt"> ***II     Redni zakonodajni postopek (druga obravnava)</p><p margin-bottom="0pt" margin-left="36.85pt" margin-right="0pt" margin-top="0pt" text-indent="-36.85pt">  ***III     Redni zakonodajni postopek (tretja obravnava)</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt"> </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt">(Vrsta postopka je odvisna od pravne podlage, ki je predlagana v osnutku akta.)</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="100%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table><table border-collapse="collapse" margin-left="83.4pt" width="290.55pt" cellspacing="0"><tr><td border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-style="italic" font-weight="bold">Spremembe osnutka akta</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt"> </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt">Pri spremembah, ki jih predlaga Parlament, je spremenjeno besedilo k osnutku akta označeno s <span font-style="italic" font-weight="bold">krepkim poševnim tiskom</span>. Besedilo, zapisano v <span font-style="italic">navadnem poševnem tisku</span>, označuje tehničnim službam namenjeni del osnutka akta s predlaganimi popravki, ki se upoštevajo pri pripravi končnega besedila (na primer očitne napake ali izpustitve v zadevni jezikovni različici). O teh popravkih odločajo pristojne tehnične službe.</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt"> </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt">Glava vsakega predloga spremembe k obstoječemu aktu, ki se ga želi spremeniti z osnutkom akta, vsebuje še tretjo in četrto vrstico. Tretja vrstica navaja obstoječi akt, četrta pa zadevno določbo tega akta. Besedilo, ki povzema določbo obstoječega akta, ki jo Parlament želi spremeniti, medtem ko v osnutku akta ni bila spremenjena, je označeno s <span font-weight="bold">krepkim tiskom</span>. Morebitni izbrisi tovrstnega besedila so označeni z <span font-weight="bold">[...]</span>.</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt"> </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-indent="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="100%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table></Legend><Toc><Title><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="12pt" text-align="center"><span font-weight="bold">VSEBINA</span></p></Title><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">OSNUTEK ZAKONODAJNE RESOLUCIJE EVROPSKEGA PARLAMENTA......................5</p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">OBRAZLOŽITEV.....................................................................................................................11</p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">POSTOPEK..............................................................................................................................16</p></Toc><Section><Title-Section><span font-weight="bold">OSNUTEK ZAKONODAJNE RESOLUCIJE EVROPSKEGA PARLAMENTA</span></Title-Section><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">o predlogu uredbe Evropskega parlamenta in Sveta o spremembi Uredbe (ES) št. 726/2004 glede farmakovigilance </span></p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">(<ANCHOR href="#reds:iEcCom/COM-2012-0051" data-rel="reds" redmap-uri="/reds:iEcCom/COM-2012-0051">COM(2012)0051</ANCHOR> – C7‑0034/2012 – <ANCHOR href="#reds:DirContProc/COD-2012-0023" data-rel="reds" redmap-uri="/reds:DirContProc/COD-2012-0023">2012/0023(COD)</ANCHOR>)</span></p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">(Redni zakonodajni postopek: prva obravnava)</span></p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic">Evropski parlament</span>,</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">–   ob upoštevanju predloga Komisije Evropskemu parlamentu in Svetu (<ANCHOR href="#reds:iEcCom/COM-2012-0051" data-rel="reds" redmap-uri="/reds:iEcCom/COM-2012-0051">COM(2012)0051</ANCHOR>),</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">–   ob upoštevanju člena 294(2) in člena 114 ter člena 168(4)(c) Pogodbe o delovanju Evropske unije, na podlagi katerih je Komisija podala predlog Parlamentu (C7‑0034/2012),</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">–   ob upoštevanju člena 294(3) Pogodbe o delovanju Evropske unije,</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">–   ob upoštevanju člena 55 Poslovnika,</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">–   ob upoštevanju poročila Odbora za okolje, javno zdravje in varnost hrane (<ANCHOR href="#reds:iPlRp/A-7-2012-0164" data-rel="reds" redmap-uri="/reds:iPlRp/A-7-2012-0164">A7-0164/2012</ANCHOR>),</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">1.  sprejme stališče v prvi obravnavi, kakor je določeno v nadaljevanju;</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">2.  poziva Komisijo, naj zadevo ponovno predloži Parlamentu, če namerava svoj predlog bistveno spremeniti ali nadomestiti z drugim besedilom;</p><p margin-bottom="12pt" margin-left="17.85pt" margin-right="0pt" margin-top="0pt" text-indent="-17.85pt">3.  naroči svojemu predsedniku, naj stališče Parlamenta posreduje Svetu in Komisiji ter nacionalnim parlamentom.</p><Amd-List><Amd><Ti-Amd><Ref-Amd><span font-weight="bold">Predlog spremembe  <Num-Amd num="1">1</Num-Amd></span></Ref-Amd><Location><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-weight="bold">Predlog uredbe</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Uvodna izjava 1</span></p></Location></Ti-Amd><Line-Amd><Old><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Besedilo, ki ga predlaga Komisija</span></p></Old><New><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Predlog spremembe</span></p></New></Line-Amd><Line-Amd><Old><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">(1)<span font-style="italic" font-weight="bold"> </span>Za zagotovitev preglednosti nadzora odobrenih zdravil mora seznam zdravil, ki jih je treba dodatno spremljati, uveden z Uredbo<span font-style="italic" font-weight="bold"> </span>(ES) št. 726/2004 Evropskega parlamenta in Sveta z dne 31. marca 2004 o postopkih Skupnosti za pridobitev dovoljenja za promet in nadzor zdravil za humano in veterinarsko uporabo ter o ustanovitvi Evropske agencije za zdravila, kakor je bila spremenjena z Uredbo<span font-style="italic" font-weight="bold"> </span>(EU) št. 1235/2010, sistematično vključevati zdravila, za katera veljajo varnostni pogoji po pridobitvi dovoljenja za promet.</p></Old><New><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">(1)<span font-style="italic" font-weight="bold"> </span>Za zagotovitev preglednosti nadzora odobrenih zdravil mora seznam zdravil, ki jih je treba dodatno spremljati, uveden z Uredbo<span font-style="italic" font-weight="bold"> </span>(ES) št. 726/2004 Evropskega parlamenta in Sveta z dne 31. marca 2004 o postopkih Skupnosti za pridobitev dovoljenja za promet in nadzor zdravil za humano in veterinarsko uporabo ter o ustanovitvi Evropske agencije za zdravila, kakor je bila spremenjena z Uredbo<span font-style="italic" font-weight="bold"> </span>(EU) št. 1235/2010, sistematično vključevati zdravila, za katera veljajo<span font-style="italic" font-weight="bold"> nekateri</span> varnostni pogoji po pridobitvi dovoljenja za promet.</p></New></Line-Amd></Amd><Amd><Ti-Amd><Ref-Amd><span font-weight="bold">Predlog spremembe  <Num-Amd num="2">2</Num-Amd></span></Ref-Amd><Location><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-weight="bold">Predlog uredbe</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Člen 1 – točka 4</span></p></Location><Loc-Old><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Uredba (ES) št. 726/2004</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold"><span font-weight="normal">Člen 23 – odstavek 1 – točki c in d</span></span></p></Loc-Old></Ti-Amd><table border-collapse="collapse" margin-left="0pt" width="487.60pt" cellspacing="0"><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="100%" rowspan="1" colspan="2"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Besedilo, ki ga predlaga Komisija</span></p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Predlog spremembe</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">(c)<span font-style="italic" font-weight="bold"> </span>zdravil, ki so odobrena v skladu s to uredbo in za katera veljajo pogoji iz točk<span font-style="italic" font-weight="bold"> (c), (ca), </span>(cb) in<span font-style="italic" font-weight="bold"> </span>(cc) člena 9(4) ali iz člena 10a<span font-style="italic" font-weight="bold">,</span> člena 14(7) in<span font-style="italic" font-weight="bold"> </span>(8)<span font-style="italic" font-weight="bold"> ter člena 21(2)</span>;</p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">(c)<span font-style="italic" font-weight="bold"> </span>zdravil, ki so odobrena v skladu s to uredbo in za katera veljajo pogoji iz točk<span font-style="italic" font-weight="bold"> </span>(cb) in<span font-style="italic" font-weight="bold"> </span>(cc) člena 9(4) ali iz člena 10a<span font-style="italic" font-weight="bold"> ter</span> člena 14(7) in<span font-style="italic" font-weight="bold"> </span>(8);</p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">(d)<span font-style="italic" font-weight="bold"> </span>zdravil, odobrenih v skladu z Direktivo 2001/83/ES in za katera veljajo pogoji iz <span font-style="italic" font-weight="bold">členov </span>21a<span font-style="italic" font-weight="bold">, </span>22<span font-style="italic" font-weight="bold">, </span>22a<span font-style="italic" font-weight="bold"> in 104a</span> navedene direktive.</p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">(d)<span font-style="italic" font-weight="bold"> </span>zdravil, odobrenih v skladu z Direktivo 2001/83/ES in za katera veljajo pogoji iz<span font-style="italic" font-weight="bold"> točk (b), (c) in (f) člena </span>21a<span font-style="italic" font-weight="bold"> ali</span> <span font-style="italic" font-weight="bold">členov </span>22<span font-style="italic" font-weight="bold"> in </span>22a navedene direktive.</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="12pt" text-align="center"><span font-style="italic">Obrazložitev</span></p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-style="italic">Seznam proizvodov, za katere je potrebno dodatno spremljanje, bi moral vsebovati samo proizvode, za katere veljajo najstrožji pogoji in varnostne zahteve, saj bo drugače seznam predolg in bo izgubil svoj pomen. </span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-style="italic">Samodejno bi moral vključevati vse nove proizvode, ki vsebujejo nove aktivne sestavine, ter vsa nova biosimilarna zdravila, in sicer prvih pet let. Prav tako bi morali biti samodejno vključeni vsi proizvodi, za katere se uporablja: </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">PASS (kot v primeru Mediator)</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člena 9(4)cb in 10a uredbe ter člena 21a(b) in 22a direktive.</p></footnote><span font-style="italic">; </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">PAES</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člena 9(4)cc in 10a uredbe ter člena 21a(f) in 22a direktive.</p></footnote><span font-style="italic">;</span><span font-style="italic" vertical-align="super"> </span><span font-style="italic"> </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">strožja pravila kot običajno pri poročanju o neželenih učinkih</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člen 9(4)cb uredbe in člen 21a(c) direktive.</p></footnote><span font-style="italic">; </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">pogojno dovoljenje za promet (tj. zaradi neizpolnjenih zdravstvenih potreb)</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člen 14(7) uredbe.</p></footnote><span font-style="italic">;</span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">izredno dovoljenje za promet (tj. za „bolezni sirote“)</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člen 14(8) uredbe in člen 22 direktive.</p></footnote><span font-style="italic">.</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-style="italic">Proizvode, za katere veljajo kateri koli drugi pogoji, bi bilo mogoče vključiti po presoji držav članic in Komisije po posvetovanju z odborom za oceno tveganja na področju farmakovigilance.</span></p></Amd><Amd><Ti-Amd><Ref-Amd><span font-weight="bold">Predlog spremembe  <Num-Amd num="3">3</Num-Amd></span></Ref-Amd><Location><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-weight="bold">Predlog uredbe</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Člen 1 – točka 4</span></p></Location><Loc-Old><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Uredba (ES) št. 726/2004</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold"><span font-weight="normal">Člen 23 – odstavek 1 a (novo)</span></span></p></Loc-Old></Ti-Amd><table border-collapse="collapse" margin-left="0pt" width="487.60pt" cellspacing="0"><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="100%" rowspan="1" colspan="2"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Besedilo, ki ga predlaga Komisija</span></p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Predlog spremembe</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">1a. Na zahtevo Komisije in po posvetu z odborom za oceno tveganja na področju farmakovigilance se lahko na seznam uvrstijo tudi zdravila, ki so odobrena v skladu s to uredbo, pod pogoji iz točk (c) in (ca) člena 9(4) in iz člena 21(2).</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">Na zahtevo pristojnega nacionalnega organa in po posvetu z odborom za oceno tveganja na področju farmakovigilance se lahko na seznam uvrstijo tudi zdravila, odobrena v skladu z Direktivo 2001/83/ES in pod pogoji iz točk (d) in (e) člena 21a in člena 104a navedene direktive.</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="12pt" text-align="center"><span font-style="italic">Obrazložitev</span></p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-style="italic">Seznam proizvodov, za katere je potrebno dodatno spremljanje, bi moral vsebovati samo proizvode, za katere veljajo najstrožji pogoji in varnostne zahteve, saj bo drugače seznam predolg in bo izgubil svoj pomen. </span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-style="italic">Samodejno bi moral vključevati vse nove proizvode, ki vsebujejo nove aktivne sestavine, ter vsa nova biosimilarna zdravila, in sicer prvih pet let. Prav tako bi morali biti samodejno vključeni vsi proizvodi, za katere se uporablja: </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">PASS (kot v primeru Mediator)</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člena 9(4)cb in 10a uredbe ter člena 21a(b) in 22a direktive.</p></footnote><span font-style="italic">; </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">PAES</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člena 9(4)cc in 10a uredbe ter člena 21a(f) in 22a direktive.</p></footnote><span font-style="italic">;</span><span font-style="italic" vertical-align="super"> </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">strožja pravila kot običajno pri poročanju o neželenih učinkih</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člen 9(4)cb uredbe in člen 21a(c) direktive.</p></footnote><span font-style="italic">; </span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">pogojno dovoljenje za promet (tj. zaradi neizpolnjenih zdravstvenih potreb)</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člen 14(7) uredbe.</p></footnote><span font-style="italic">;</span></p><p margin-bottom="0pt" margin-left="34pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12.75pt"> </span></span><span font-style="italic">izredno dovoljenje za promet (tj. za „bolezni sirote“)</span><footnote><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"> Člen 14(8) uredbe in člen 22 direktive.</p></footnote><span font-style="italic">.</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-style="italic">Proizvode, za katere veljajo kateri koli drugi pogoji, bi bilo mogoče vključiti po presoji držav članic in Komisije po posvetovanju z odborom za oceno tveganja na področju farmakovigilance.</span></p></Amd><Amd><Ti-Amd><Ref-Amd><span font-weight="bold">Predlog spremembe  <Num-Amd num="4">4</Num-Amd></span></Ref-Amd><Location><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-weight="bold">Predlog uredbe</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Člen 1 – točka 4</span></p></Location><Loc-Old><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Uredba (ES) št. 726/2004</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold"><span font-weight="normal">Člen 23 – odstavek 4</span></span></p></Loc-Old></Ti-Amd><table border-collapse="collapse" margin-left="0pt" width="487.60pt" cellspacing="0"><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="100%" rowspan="1" colspan="2"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Besedilo, ki ga predlaga Komisija</span></p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Predlog spremembe</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">4.<span font-style="italic" font-weight="bold"> </span>Za zdravila s seznama se v povzetek glavnih značilnosti zdravila in navodilo za uporabo vključi izjava<span font-style="italic" font-weight="bold"> </span>„Za to zdravilo se izvaja dodatno spremljanje“.<span font-style="italic" font-weight="bold"> </span>Pred navedeno izjavo je črn simbol, ki ga Komisija po priporočilu svetovalnega odbora za oceno tveganja na področju farmakovigilance izbere do<span font-style="italic" font-weight="bold"> 2. januarja 2012</span>, za njo pa ustrezna standardna obrazložitev.</p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">4.<span font-style="italic" font-weight="bold"> </span>Za zdravila s seznama se v povzetek glavnih značilnosti zdravila in navodilo za uporabo vključi izjava<span font-style="italic" font-weight="bold"> </span>„Za to zdravilo se izvaja dodatno spremljanje“.<span font-style="italic" font-weight="bold"> </span>Pred navedeno izjavo je črn simbol, ki ga Komisija po priporočilu svetovalnega odbora za oceno tveganja na področju farmakovigilance izbere do<span font-style="italic" font-weight="bold"> 2. julija 2013</span>, za njo pa ustrezna standardna obrazložitev.</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt" text-align="center"><span font-style="italic">Obrazložitev</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-style="italic">Predlog spremembe odpravlja napako iz oblikovanja sedanje zakonodaje. Odbor za oceno tveganja na področju farmakovigilance bo ustanovljen julija 2012, zato obdobje 12 mesecev začne teči šele takrat.</span></p></Amd><Amd><Ti-Amd><Ref-Amd><span font-weight="bold">Predlog spremembe  <Num-Amd num="5">5</Num-Amd></span></Ref-Amd><Location><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-weight="bold">Predlog uredbe</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Člen 1 – točka 4 a (novo)</span></p></Location><Loc-Old><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Uredba (ES) št. 726/2004</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Člen 67 – odstavek 3 – pododstavek 2 a (novo)</p></Loc-Old></Ti-Amd><table border-collapse="collapse" margin-left="0pt" width="487.60pt" cellspacing="0"><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="100%" rowspan="1" colspan="2"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Besedilo, ki ga predlaga Komisija</span></p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Predlog spremembe</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">(4a) Členu 67(3) se dodata naslednja pododstavka: </span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">„Z odstopanjem od člena 70(1) pristojbine za storitve, ki jih zagotavlja Agencija na področju farmakovigilance, skupina za usklajevanje pa pri izpolnjevanju svojih nalog iz prvega pododstavka, določi Komisija.</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">V ta namen Komisija po posvetovanju z Agencijo z delegiranimi akti v skladu s členom 87ba in pod pogoji iz členov 87c in 87d sprejme ukrepe, ki dopolnjujejo tretji pododstavek glede strukture in višine teh pristojbin.“</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="12pt" text-align="center"><span font-style="italic">Obrazložitev</span></p><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic">Da bi zagotovili dosledno izvajanje novih določb o farmakovigilanci, je treba nujno pooblastiti Evropsko agencijo za zdravila, da bo imetnikom dovoljenja za promet zaračunavala pristojbine za izpolnjevanje nalog farmakovigilance. </span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic">Zato bi bilo treba na Komisijo prenesti pooblastilo za sprejemanje delegiranih aktov v skladu s členom 290 Pogodbe o delovanju Evropske unije, da bi dopolnila določbe v členu 67(3) glede storitev, ki jih na področju farmakovigilance zagotavlja Agencija ali skupina za usklajevanje.</span></p></Amd><Amd><Ti-Amd><Ref-Amd><span font-weight="bold">Predlog spremembe  <Num-Amd num="6">6</Num-Amd></span></Ref-Amd><Location><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-weight="bold">Predlog uredbe</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Člen 1 – točka 4 b (novo)</span></p></Location><Loc-Old><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Uredba (ES) št. 726/2004</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Člen 87 b – odstavek 1 a (novo) </p></Loc-Old></Ti-Amd><table border-collapse="collapse" margin-left="0pt" width="487.60pt" cellspacing="0"><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="100%" rowspan="1" colspan="2"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Besedilo, ki ga predlaga Komisija</span></p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Predlog spremembe</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">(4b) V členu 87b se vstavi naslednji odstavek:</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">„1a. Pooblastilo za sprejemanje delegiranih aktov iz člena 67(3) se prenese na Komisijo za obdobje petih let od 1. julija 2012. Komisija pripravi poročilo o prenesenem pooblastilu najpozneje šest mesecev pred koncem petletnega obdobja. Prenos pooblastila se samodejno podaljša za enaka obdobja, razen če ga Evropski parlament ali Svet ne prekliče v skladu s členom 87c.“</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table></Amd><Amd><Ti-Amd><Ref-Amd><span font-weight="bold">Predlog spremembe  <Num-Amd num="7">7</Num-Amd></span></Ref-Amd><Location><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="12pt"><span font-weight="bold">Predlog uredbe</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Člen 1 – točka 4 c (novo)</span></p></Location><Loc-Old><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Uredba (ES) št. 726/2004</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Člen 87 c – odstavek 1</p></Loc-Old></Ti-Amd><table border-collapse="collapse" margin-left="0pt" width="487.60pt" cellspacing="0"><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="100%" rowspan="1" colspan="2"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Besedilo, ki ga predlaga Komisija</span></p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="12pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="center"><span font-style="italic">Predlog spremembe</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-style="italic" font-weight="bold">(4c) Člen 87c(1) se nadomesti z naslednjim:</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td padding="0 17pt 0 17pt" vertical-align="top" width="50%" rowspan="1" colspan="1"><p margin-bottom="6pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">„1. Pooblastilo iz člena 10b </span><span font-style="italic" font-weight="bold">in člena 67(3)</span><span font-weight="bold"> lahko kadar koli prekliče Evropski parlament ali Svet.“</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="50%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table></Amd></Amd-List></Section><Section><Title-Section><span font-weight="bold">OBRAZLOŽITEV</span></Title-Section><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-weight="bold">Podlaga za revizijo</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">Decembra 2010 sta se Evropski parlament in Svet dogovorila o reviziji pravil s področja farmakovigilance na ravni EU s sprejetjem Direktive 2010/84/EU in Uredbe 1235/2010. Nova zakonodaja naj bi se začela uporabljati julija 2012. Poročevalka meni, da bo niz ukrepov, sprejetih s to novo zakonodajo, izboljšal varnost zdravil na ravni EU z okrepitvijo vloge Evropske agencije za zdravila pri zbiranju signalov in odzivu nanje ter s tesnejšim sodelovanjem med državami članicami.</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">Zaradi večje preiskave varnosti zdravil v Franciji v primeru Mediator iz leta 2011 (gl. spodaj) pa se je sprožil poziv k nujnemu pregledu sistemov farmakovigilance v EU. Evropska komisija se je odzvala s testom izjemnih situacij, s katerim je preučila zakonodajo, ki je bila v veljavi decembra 2010, da bi določila, kaj vse je treba glede na izkušnjo s primerom Mediator še upoštevati. Rezultati testa so pokazali, da je nova zakonodaja sicer okrepila farmakovigilanco na ravni EU, da pa je treba kljub temu odpraviti nekatere pomanjkljivosti, ki bi jih sistem EU lahko vseboval. Za obravnavanje teh težav Komisija predlaga nekatere dodatne spremembe Direktive 2010/84/EU in Uredbe 1235/2010. </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">Poročevalka upa, da se bosta Svet in Parlament v interesu javnega zdravja sporazumela glede teh sprememb v prvi obravnavi, da jih bo mogoče vključiti v zakonodajo pred začetkom izvajanja, ki je predvideno za julij 2012. Da bi se čim prej sporazumeli, se poročevalka osredotoča na spremembe, ki izvirajo iz spoznanj, temelječih na primeru Mediator, ne odpira pa drugih vprašanj. Poročevalcu v senci se zahvaljuje za sodelovanje pri tej zadevi.  </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-weight="bold">Primer Mediator v Franciji</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">Mediator je zdravilo, ki ga je izdelalo francosko podjetje Servier, zanj pa je bila z nacionalnimi postopki v vrsti držav EU (Francija, Portugalska, Luksemburg, Grčija, Italija in Španija) izdana licenca za zdravljenje sladkorne bolezni tipa 2. Njegova glavna sestavina je benfluoreks, o katerega neželenih učinkih so poročali že leta 1999, saj naj bi povzročal težave s srčno zaklopko. V ZDA in EU so v poznih devetdesetih letih vzeli s trga podobni učinkovini z anorektičnim učinkom – deksfenfluramin in fenfluramin. </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">Kljub temu so zdravilo mediator v Evropi, zlasti pa Franciji, pogosto predpisovali. Ocenjujejo, da so zdravilo do leta 2009, ko so ga končno umaknili s trga, predpisali 5 milijonom ljudem in da je bilo med 50 najpogosteje predpisanimi zdravili v Franciji. Obstajajo dokazi, da zdravila niso predpisovali samo za sladkorno bolezen, ampak na splošno za zaviranje teka. Ocenjuje se, da zaradi tega zdravila umrlo od petsto do dva tisoč ljudi.</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">V sporočilu Evropske agencije za zdravila iz januarja 2011 je zapisano, da so regulatorji na različnih srečanjih na evropski ravni že vse od leta 1998 izražali zaskrbljenost zaradi zdravila mediator in njegove aktivne sestavine benfluoreks. Ocena italijanskih organov iz leta 2000 vsebuje priporočilo, naj imetnik dovoljenja za promet preuči utemeljenost teh skrbi s študijo, vendar se je glede na poročilo francoskega senata kljub temu, da je bil protokol zanjo sprejet februarja 2001, študija začela izvajati šele leta 2006, zaključena pa je bila leta 2009. Kljub vsej izpričani zaskrbljenosti ni bila sprejeta odločitev, da bi zdravilo mediator na ravni EU uradno znanstveno ocenil tedanji odbor za zdravila za uporabo v humani medicini, kar pomeni, da regulatorji niso sprejeli nadaljnjih ukrepov. Leta 2003 je podjetje Servier pustilo poteči dovoljenje za promet v Španiji in Italiji, vendar po sedanjih pravilih ne pride do preiskave, kadar podjetje ne zaprosi za novo dovoljenje. Podjetje Servier je trdilo, da se je umaknilo zaradi tržnih razlogov, države članice pa so bile o odločitvi preprosto obveščene v redni publikaciji Evropske agencije za zdravila „Drug Monitor”. Šele novembra 2009 so prišli v Franciji na dan novi dokazi. Francija je začasno ustavila dovoljenje za prodajo, zdravilo mediator je bilo končno predloženo odboru za zdravila za uporabo v humani medicini in dovoljenje za prodajo v EU preklicano. </p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">V Franciji poteka več kazenskih preiskav v zvezi s tem zdravilom, eno od njih vodi državni tožilec, ki preiskuje podjetje Servier zaradi zavajanja in nenamernega uboja.</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-weight="bold">V odziv na primer Mediator je Komisija predlagala spremembe obstoječe zakonodaje o framakovigilanci </span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">Test izjemnih situacij, ki ga je opravila Komisija, je pokazal, da so kljub mnogim izboljšavam v novem sistemu potrebne nadaljnje spremembe za zapolnitev morebitnih vrzeli. Samodejni nujni postopek (člen 107i direktive). </p><p margin-bottom="0pt" margin-left="35.7pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-17.85pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12pt"> </span></span><span font-weight="bold">Samodejni nujni postopek</span> (člen 107i direktive). V zakonodaji iz leta 2010 je že določen seznam primerov, ko se sproži nujni postopek (npr. če država umakne zdravilo), vendar imajo države članice pri tem nekaj diskrecijske pravice. Nov primer, ki bi sprožil nujni postopek (člen 107i direktive). </p><p margin-bottom="0pt" margin-left="36pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-18pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12pt"> </span></span><span font-weight="bold">Nov primer, ki bi sprožil nujni postopek</span> (člen 107i direktive). Če se podjetje odloči, da ne bo zaprosilo za podaljšanje dovoljenja za promet zaradi varnostnih razlogov (kot se je zgodilo v primeru Mediator), bi se moral sprožiti nujni postopek. </p><p margin-bottom="0pt" margin-left="36pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-18pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12pt"> </span></span><span font-weight="bold">Pojasnitev obveznosti glede preglednosti za podjetja</span> (člen 123(2) direktive). Če podjetje samo umakne zdravilo ali ne zaprosi ponovno za dovoljenje za promet, mora izrecno izjaviti, ali je to zaradi varnostnega zadržka. (Ko podjetje Servier ni ponovno zaprosilo za dovoljenje za zdravilo mediator v Italiji in Španiji, je trdilo, da je to zaradi tržnih razlogov.) </p><p margin-bottom="0pt" margin-left="36pt" margin-right="0pt" margin-top="0pt" text-align="justify" text-indent="-18pt"><span font-style="normal" font-weight="normal" text-decoration="none">·<span padding-left="12pt"> </span></span><span font-weight="bold">Daljši seznam zdravil, ki jih je treba dodatno spremljati</span> (člen 23 uredbe). Seznam zdravil s črnim simbolom, ki jih je treba dodatno spremljati, bi moral dosledno vključevati vsa zdravila, za katere so potrebne študije o varnosti zdravila po pridobitvi dovoljenja za promet ali kakšni drugi pogoji ali zahteve. V zakonodaji iz leta 2010 je Komisija sprva predlagala, da je treba tako opredeliti vsa zdravila, za katera veljajo posebni pogoji. Koncept „dodatnega spremljanja” je pomembno orodje za zagotavljanje „obveščenega” bolnika in večje ozaveščenosti med zdravstvenimi delavci o potrebi po iskanju neželenih učinkov in poročanju o njih. Hkrati lahko spodbuja podjetja k temu, da izvajajo študije po pridobitvi dovoljenja za promet. Med pogajanji pa je bila ta samodejna zahteva umaknjena in uvedena diskretnost, tako da lahko organi dodajajo ta zdravila za vsak primer posebej. Kot je zgoraj omenjeno, je bila za zdravilo mediator določena študija o varnosti zdravila po pridobitvi dovoljenja za promet, ki pa ni bila zaključena do leta 2009, torej osem let po tem, ko je bil sprejet zapisnik o študiji.</p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify"><span font-weight="bold">Dodatni predlogi sprememb poročevalke</span></p><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt" text-align="justify">Poročevalka se v glavnem strinja z usmerjenostjo predlogov Komisije, ki dodatno krepijo sistem farmakovigilance na ravni EU. Namen štirih dodatnih predlaganih sprememb, ki so podrobno razložene pod vsakim členom, je zagotoviti obvladljivost obsega dela odbora za oceno tveganja na področju farmakovigilance ter polno vključenost bolnikov in zdravstvenih delavcev v ta proces. </p><p><span font-weight="bold">Zakonodajna sled: predlog uredbe in direktive Evropskega parlamenta in Sveta o farmakovigilanci zdravil za humano uporabo. </span></p><p>Kot poročevalka za poročilo Evropskega parlamenta za farmakovigilanco se je Linda McAvan srečala s predstavniki naslednjih organizacij in organov, jih sprejela ali pridobila njihovo mnenje:<span font-weight="bold" text-decoration="underline"> </span></p><table border-collapse="collapse" margin-left="0pt" width="428.40pt" cellspacing="0"><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Industrija</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Evropsko združenje za generična zdravila (EGA) </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Evropska federacija farmacevtskih panog in združenj (EFPIA)</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">EuropaBio </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Reckitt Benckiser</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">British Chamber of Commerce</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Novartis </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Sanofi-Aventis </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Sandoz International </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Servier</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Astro Zeneka</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Sidley Austin</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Teva</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Skupine pacientov, strokovnjakov ali potrošnikov</span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Evropski forum pacientov</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Evropsko potrošniško združenje (BEUC)</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Farmacevtska skupina Evropske unije (PGEU)</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Prescrire in Mednarodno združenje biltenov o zdravilih (ISDB) </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Forum Zdravila v Evropi </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Zveza EU za javno zdravje (EPHA) </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Regulativne agencije EU in nacionalne regulativne agencije </span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Evropska agencija za zdravila (EMA) </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">stalno predstavništvo Velike Britanije v EU in Regulativna agencija Velike Britanije za zdravila in zdravstvo (MHRA) </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">stalno predstavništvo Belgije v EU in Federalna agencija za zdravila in zdravstvene proizvode </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="100%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table><p><span font-weight="bold">Zakonodajna sled: 2012 – predlog uredbe in direktive Evropskega parlamenta in Sveta o farmakovigilanci zdravil za humano uporabo. </span></p><p>Kot poročevalka za poročilo Evropskega parlamenta za farmakovigilanco se je Linda McAvan srečala s predstavniki naslednjih organizacij in organov, jih sprejela ali pridobila njihovo mnenje:<span font-weight="bold" text-decoration="underline"> </span></p><table border-collapse="collapse" margin-left="0pt" width="428.40pt" cellspacing="0"><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"><span font-weight="bold">Regulativne agencije EU in nacionalne regulativne agencije </span></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt"> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Evropska agencija za zdravila (EMA) </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">Evropska komisija </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 0.5pt" border-left="solid #000000 0.5pt" border-right="solid #000000 0.5pt" border-top="solid #000000 0.5pt" padding="0pt 5.4pt 0pt 5.4pt" vertical-align="top" width="100%" rowspan="1" colspan="1"><p margin-bottom="0pt" margin-left="0pt" margin-right="0pt" margin-top="0pt">stalno predstavništvo Danske v EU ter danska agencija za zdravila in zdravstvene proizvode</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="100%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table></Section><Section><Title-Section><span font-weight="bold">POSTOPEK</span></Title-Section><table border-collapse="collapse" margin-left="3.95pt" width="481.85pt" cellspacing="0"><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Naslov</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="61.76%" rowspan="1" colspan="4"><p>Sprememba Uredbe (ES) št. 726/2004 glede farmakovigilance</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Referenčni dokumenti</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="61.76%" rowspan="1" colspan="4"><p><ANCHOR href="#reds:iEcCom/COM-2012-0051" data-rel="reds" redmap-uri="/reds:iEcCom/COM-2012-0051">COM(2012)0051</ANCHOR> – C7-0034/2012 – <ANCHOR href="#reds:DirContProc/COD-2012-0023" data-rel="reds" redmap-uri="/reds:DirContProc/COD-2012-0023">2012/0023(COD)</ANCHOR></p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Datum predložitve EP</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>10.2.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Pristojni odbor</span></p><p>       Datum razglasitve na zasedanju</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>ENVI</p><p>16.2.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Odbori, zaprošeni za mnenje</span></p><p>       Datum razglasitve na zasedanju</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>ITRE</p><p>16.2.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p>IMCO</p><p>16.2.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Odbori, ki niso podali mnenja</span></p><p>       Datum sklepa</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>ITRE</p><p>27.2.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p>IMCO</p><p>29.2.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Poročevalec/-ka</span></p><p>       Datum imenovanja</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>Linda McAvan</p><p>20.12.2011</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Obravnava v odboru</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>22.3.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p>26.4.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Datum sprejetja</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>8.5.2012</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.3%" rowspan="1" colspan="1"><p> </p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Izid končnega glasovanja</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="none #000000 0pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="15.88%" rowspan="1" colspan="1"><p>+:</p><p>–:</p><p>0:</p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="45.89%" rowspan="1" colspan="3"><p>50</p><p>0</p><p>0</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Poslanci, navzoči pri končnem glasovanju</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="solid #000000 1pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="61.76%" rowspan="1" colspan="4"><p>Elena Oana Antonescu, Kriton Arsenis, Sophie Auconie, Pilar Ayuso, Paolo Bartolozzi, Lajos Bokros, Martin Callanan, Nessa Childers, Chris Davies, Esther de Lange, Anne Delvaux, Bas Eickhout, Edite Estrela, Karl-Heinz Florenz, Elisabetta Gardini, Matthias Groote, Françoise Grossetête, Cristina Gutiérrez-Cortines, Satu Hassi, Jolanta Emilia Hibner, Karin Kadenbach, Christa Klaß, Jo Leinen, Peter Liese, Kartika Tamara Liotard, Linda McAvan, Radvilė Morkūnaitė-Mikulėnienė, Vladko Todorov Panajotov (Vladko Todorov Panayotov), Antonija Prvanova (Antonyia Parvanova), Andres Perello Rodriguez, Mario Pirillo, Pavel Poc, Anna Rosbach, Oreste Rossi, Dagmar Roth-Behrendt, Richard Seeber, Anja Weisgerber, Åsa Westlund, Glenis Willmott, Marina Yannakoudakis</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Namestniki, navzoči pri končnem glasovanju</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="61.76%" rowspan="1" colspan="4"><p>Margrete Auken, Nikos Hrizogelos (Nikos Chrysogelos), João Ferreira, Filip Kaczmarek, Toine Manders, Alojz Peterle, Christel Schaldemose, Marita Ulvskog, Vladimir Uručev (Vladimir Urutchev), Andrea Zanoni</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border-bottom="solid #000000 1pt" border-left="solid #000000 1pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="38.24%" rowspan="1" colspan="1"><p><span font-weight="bold">Datum predložitve</span></p></td><td border-bottom="solid #000000 1pt" border-left="none #000000 0pt" border-right="solid #000000 1pt" border-top="none #000000 0pt" padding="3.95pt 3.95pt 3.95pt 3.95pt" vertical-align="top" width="61.76%" rowspan="1" colspan="4"><p>12.7.2012</p></td><td rowspan="1" colspan="1"></td></tr><tr><td border="none" margin="0" padding="0" width="38.24%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="15.88%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="15.3%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="15.3%" rowspan="1" colspan="1"></td><td border="none" margin="0" padding="0" width="15.3%" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></table></Section></Report>